Genmab files 6-K on capital increase from warrants

Genmab A/S filed a Form 6-K as a foreign private issuer for August 2025.

Rhea-AI Filing Summary

Genmab A/S filed a Form 6-K as a foreign private issuer for August 2025. The report primarily forwards an attached company announcement describing a capital increase in Genmab resulting from the exercise of employee warrants. The filing also specifies that this 6-K is incorporated by reference into several existing Genmab Form S-8 registration statements covering employee equity compensation plans.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Genmab (GMAB) report in this August 2025 Form 6-K?

Genmab reports the submission of a company announcement describing a capital increase resulting from employee warrant exercises. The Form 6-K mainly serves to furnish this announcement and link it into existing registration statements.

Why did Genmab (GMAB) have a capital increase according to the filing?

The capital increase at Genmab resulted from the exercise of employee warrants. When employees exercise warrants, new shares are typically issued, which increases the company’s share capital compared with the prior level.

How is this Genmab (GMAB) Form 6-K used with existing registration statements?

The Form 6-K is expressly incorporated by reference into Genmab’s Form S-8 registration statements. This means the information it contains becomes legally part of those employee share plan registration documents going forward.

Which exhibits are included with this Genmab (GMAB) Form 6-K?

The filing lists one exhibit, numbered 99.1, described as a company announcement dated August 12, 2025. That announcement covers the capital increase in Genmab arising from the exercise of employee warrants by participants.

Who signed this Genmab (GMAB) Form 6-K and in what capacity?

The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano. He is identified in the document as the company’s Executive Vice President and Chief Financial Officer, acting as an authorized representative.

Does this Genmab (GMAB) Form 6-K contain detailed financial results?

The document itself does not present detailed financial results. It focuses on furnishing an exhibit about a capital increase from employee warrant exercises and on incorporating that information into existing Form S-8 registrations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2025 - 03:11 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF AUGUST 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated August 12, 2025: Capital Increase in Genmab as a Result of Employee Warrant Exercise

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: August 12, 2025